Related Experiment Video
Updated: Jun 19, 2026
Targeted Knockdown of Genes in the Choroid Plexus
Published on: June 16, 2023
Recombinant TCR ligand reverses clinical signs and CNS damage of EAE induced by recombinant human MOG
Sushmita Sinha1, Sandhya Subramanian, Ashley Emerson-Webber
1Neuroimmunology Research, Portland VA Medical Center, 3710 SW U.S. Veterans Hospital Rd., Portland, OR 97239, USA.
Abstract:
Increasing evidence suggests that in addition to T cell-dependent effector mechanisms, autoantibodies are also involved in the pathogenesis of MS, including demyelinating antibodies specific for myelin oligodendrocyte glycoprotein (MOG). Our previous studies have demonstrated that recombinant T cell receptor ligands (RTLs) are very effective for treating T cell-mediated experimental autoimmune encephalomyelitis (EAE). In order to expand the scope of RTL therapy in MS patients, it was of interest to study RTL treatment of EAE involving a demyelinating antibody component. Therefore, we evaluated the therapeutic effects of RTL551, specific for T cells reactive to mouse (m)MOG-35-55 peptide, on EAE induced with recombinant human (rh)MOG in C57BL/6 mice. We report that RTL551 therapy can reverse disease progression and reduce demyelination and axonal damage induced by rhMOG without suppressing the anti-MOG antibody response. This result suggests that T cell-mediated inflammation and associated blood-brain barrier dysfunction are the central contributors to EAE pathogenesis and that successful regulation of these key players restricts potential damage by demyelinating antibodies. The results of our study lend support for the use of RTL therapy for treatment of MS subjects whose disease includes inflammatory T cells as well as those with an additional antibody component.
Insights
Recombinant T cell receptor ligands (RTLs) effectively treat experimental autoimmune encephalomyelitis (EAE) by reducing inflammation and damage, even with demyelinating antibodies. This suggests RTL therapy is promising for multiple sclerosis (MS) patients with T cell and antibody components.
Area of Science:
- Neuroimmunology
- Autoimmune Diseases
- Therapeutic Development
Background:
- Multiple Sclerosis (MS) pathogenesis involves T cells and autoantibodies, including those targeting myelin oligodendrocyte glycoprotein (MOG).
- Recombinant T cell receptor ligands (RTLs) have shown efficacy in T cell-mediated experimental autoimmune encephalomyelitis (EAE).
Purpose of the Study:
- To evaluate the therapeutic potential of RTL551 in an EAE model with a demyelinating antibody component.
- To investigate the effect of RTL551 on disease progression, demyelination, and axonal damage induced by human MOG.
Main Methods:
- Induction of EAE in C57BL/6 mice using recombinant human (rh)MOG.
- Therapeutic administration of RTL551, targeting T cells reactive to mouse MOG peptide (35-55).
- Assessment of disease severity, demyelination, axonal damage, and anti-MOG antibody response.
Main Results:
- RTL551 therapy reversed EAE disease progression.
- Treatment reduced demyelination and axonal damage induced by rhMOG.
- RTL551 did not suppress the anti-MOG antibody response, indicating targeted immunomodulation.
Conclusions:
- T cell-mediated inflammation and blood-brain barrier dysfunction are key drivers of EAE pathogenesis.
- RTL therapy can mitigate damage caused by demyelinating antibodies by regulating T cell responses.
- RTL therapy holds promise for treating MS patients with both inflammatory T cell and antibody-mediated disease components.
